Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12623000166673p
Ethics application status
Submitted, not yet approved
Date submitted
8/02/2023
Date registered
17/02/2023
Date last updated
17/02/2023
Date data sharing statement initially provided
17/02/2023
Type of registration
Prospectively registered
Titles & IDs
Public title
Evaluating Prevention of Muscle Loss After Menopause Using Testosterone: The PAMELA study
Query!
Scientific title
Evaluating prevention of Muscle Loss After Menopause Using Testosterone: The PAMELA study
Query!
Secondary ID [1]
308952
0
None
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Muscle loss
328964
0
Query!
Osetopenia
328965
0
Query!
sarcopenia
329027
0
Query!
osteoporosis
329028
0
Query!
Condition category
Condition code
Reproductive Health and Childbirth
325950
325950
0
0
Query!
Menstruation and menopause
Query!
Musculoskeletal
325952
325952
0
0
Query!
Osteoporosis
Query!
Musculoskeletal
325953
325953
0
0
Query!
Other muscular and skeletal disorders
Query!
Metabolic and Endocrine
326011
326011
0
0
Query!
Other metabolic disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Application of active treatment, 1% testosterone cream, 0.5ml (10mg/ml), or placebo cream
applied transdermally daily to upper thigh or lower torso by participant for 6 months.
Compliance will be assessed by collection and weighing of returned cream containers at week 12 and week 26 after commencement of treatment.
Participants will be provided with and asked to self-administer vitamin D3 oral capsule, 1000IU/day for 26 weeks.
Query!
Intervention code [1]
325401
0
Treatment: Drugs
Query!
Comparator / control treatment
Placebo is unmedicated Androfeme 1 base formulation cream containing dl-8- tocopherol acetate (vitamin E), almond oil, butylated hydroxytoluene, carbomer 940, cetomacrogol 1000, cetostearyl alcohol, citric acid -anhydrous, triethanolamine, water purified and Phenonip® - a preservative containing hydroxybenzoates and phenoxyethanol.
0.5ml daily applied transdermally to upper thigh or buttock for 6 months
Participants will be provided with and asked to self-administer vitamin D3 oral capsule, 1000IU/day for 26 weeks.
Query!
Control group
Placebo
Query!
Outcomes
Primary outcome [1]
333801
0
Any change in body-weight corrected power (W/kg) during a two leg countermovement jump measured via the Leonardo Mechanography Ground Reaction Force Platform.
Query!
Assessment method [1]
333801
0
Query!
Timepoint [1]
333801
0
6 months post-randomisation.
Query!
Secondary outcome [1]
418339
0
Any change in grip force measured via the Leonardo Mechanography Ground Reaction Force Platform.
Query!
Assessment method [1]
418339
0
Query!
Timepoint [1]
418339
0
6 months post-randomisation.
Query!
Secondary outcome [2]
418340
0
Any change in whole body composition assessed using dual-energy X-ray absorptiometry (DXA).
Query!
Assessment method [2]
418340
0
Query!
Timepoint [2]
418340
0
6 months post-randomisation.
Query!
Secondary outcome [3]
418342
0
Any change in health-related quality of life assessed using the Short-Form 36 questionnaire.
Query!
Assessment method [3]
418342
0
Query!
Timepoint [3]
418342
0
6 months post-randomisation.
Query!
Secondary outcome [4]
418572
0
Any change in grip work (endurance) measured via the Leonardo Mechanography Ground Reaction Force Platform.
Query!
Assessment method [4]
418572
0
Query!
Timepoint [4]
418572
0
6 months post-randomisation.
Query!
Secondary outcome [5]
418573
0
Any change in measures of balance (standing with feet together eyes open/closed, tandem stance eyes open/closed, single leg stance eyes open/closed) measured via stabilometry on the Leonardo Mechanography Ground Reaction Force Platform.
Query!
Assessment method [5]
418573
0
Query!
Timepoint [5]
418573
0
6 months post-randomisation.
Query!
Secondary outcome [6]
418574
0
Any change in power assessed via the heel rise test measured via the Leonardo Mechanography Ground Reaction Force Platform.
Query!
Assessment method [6]
418574
0
Query!
Timepoint [6]
418574
0
6 months post-randomisation.
Query!
Secondary outcome [7]
418575
0
Any change in bone mineral density assessed using using DXA scans
Query!
Assessment method [7]
418575
0
Query!
Timepoint [7]
418575
0
6 months post-randomisation.
Query!
Secondary outcome [8]
418576
0
Any change in menopause-related quality of life assessed using the MENQOL questionnaire.
Query!
Assessment method [8]
418576
0
Query!
Timepoint [8]
418576
0
6 months post-randomisation.
Query!
Eligibility
Key inclusion criteria
Naturally postmenopausal women, aged 55-70 years, who are not taking medications that might influence hormone levels or muscle/bone health. Participants must be agreeable to taking vitamin D3 1000 IU/day and making no meaningful change in their exercise regime or diet over the course of the study. Participants will be required to have a body mass index between 18 and 35 kg/m2, a clinically acceptable mammogram in the preceding 2 years and clinically acceptable cervical screening test results within the preceding 5 years.
Query!
Minimum age
55
Years
Query!
Query!
Maximum age
70
Years
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
1. Body mass index <18 or >35 kg/m2
2. Current or recent (in the past 12 months) use of systemic estrogen replacement therapy or tibolone (vaginal estrogen permitted)
3. Current or recent (in the past 12 months) use of antiandrogens
4. Use of any drugs affecting bone metabolism such as bisphosphonates, denosumab, systemic corticosteroids, antineoplastic drugs, thiazide diuretics, anti-epileptic drugs, and heparin in the last 5 years
5. History of testosterone or dehydroepiandrosterone treatment in the last 5 years
6. Plans to commence a weight reduction diet for the duration of the study
7. Known allergy to almonds (a constituent of the cream)
8. Severe chronic skin disease (such as eczema or psoriasis) that is likely to interfere with transdermal drug absorption
9. Intolerance to transdermal testosterone
10. Clinically significant infection requiring systemic antibiotics
11. Undiagnosed vaginal bleeding
12. Evidence of clinical hyperandrogenism (hirsutism, androgenic alopecia, or acne) as assessed by the recruiting clinician
13. Taking herbal remedies, grapefruit juice, or medications known to be strong inducers or inhibitors of cytochrome P450 3A4 or known to interact with testosterone metabolism or reproductive hormone levels.
14. Use of protein supplementation is permitted but participants will be restricted from commencing new any new protein supplement or increasing their consumption.
15. History of smoking within the past year, active substance abuse, or alcohol consumption of more than two standard drinks per day
16. Severe musculoskeletal, neurological, or metabolic disease which might influence the results of the study
17. Present or previous systemic cancer diagnosis in the last 5 years
18. Donation of blood within the last 6 weeks or plasma within 7 days of the first dosing in this study
19. Abnormal thyroid function (abnormal thyroid stimulating hormone (TSH) value confirmed by a free T4 outside laboratory range)
20. Being considered by a chief investigator to be unsuitable for participation in the study
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is concealed by central randomisation by computer
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Allocation of participants in a 1:1 ratio to either transdermal testosterone or placebo group will be based on computer generated random numbers prepared by a statistician with no involvement in the trial. Randomization will be performed based on blocks of size 4 and 6, and stratified based on whether participants meet the current Australian guidelines for physical activity (>150 minutes moderate intensity or >75 minutes vigorous intensity exercise per week).
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
An intention-to-treat analysis, including all participants in their randomized groups regardless of their adherence to assigned treatments, will be performed in a blinded fashion. Differences between randomized groups in the changes in primary and secondary outcome measures at 26 weeks will be examined using linear mixed-effects regression models with baseline value as the covariate, fixed factors for treatment, time, and treatment x time interaction, and with an autoregressive AR(1) covariance matrix for repeated measures of individuals over time. If >5% of participants are missing their primary outcome, multiple imputation will be applied to account for missing data, with missing values imputed separately by treatment group, assuming data are missing at random. The bootstrap approach will be used to provide 95% confidence intervals and p-values if the normality assumption is questionable. Additional adjustment will be carried out in a sensitivity analysis if clinically important baseline imbalances between randomized groups are identified. Pre-specified subgroup analyses will be performed by testing a treatment by subgroup interaction in the models. Per-protocol analyses for the primary and secondary endpoints will be conducted as secondary analyses.
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
3/04/2023
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
156
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Funding & Sponsors
Funding source category [1]
313166
0
Government body
Query!
Name [1]
313166
0
National Health and Medical Research Council
Query!
Address [1]
313166
0
16 Marcus Clarke Street
Canberra, ACT 2600
Query!
Country [1]
313166
0
Australia
Query!
Primary sponsor type
University
Query!
Name
Monash University
Query!
Address
School of Public Health and Preventive Medicine
Monash University
553 St Kilda Rd
Melbourne, VIC 3004
Query!
Country
Australia
Query!
Secondary sponsor category [1]
314872
0
None
Query!
Name [1]
314872
0
Query!
Address [1]
314872
0
Query!
Country [1]
314872
0
Query!
Ethics approval
Ethics application status
Submitted, not yet approved
Query!
Ethics committee name [1]
312407
0
Monash University Human Ethics Committee
Query!
Ethics committee address [1]
312407
0
Monash Research Office, 26 Sports Walk, Monash University, Wellington Road, Clayton VIC 3800.
Query!
Ethics committee country [1]
312407
0
Australia
Query!
Date submitted for ethics approval [1]
312407
0
01/02/2023
Query!
Approval date [1]
312407
0
Query!
Ethics approval number [1]
312407
0
Query!
Summary
Brief summary
Endogenous testosterone has been associated with increased lean mass and exercise performance in young and elderly women and testosterone therapy increased lean mass in two pilot randomized controlled trials. However, our systematic review and meta-analyses found no effect of exogenous testosterone on muscle strength or performance, as prior studies have been small (<20 participants per group) and of short duration (6-16 weeks). The aim of this two-arm parallel-group randomized placebo-controlled trial is to determine whether testosterone therapy results in significant gains in muscular power over placebo in postmenopausal women. Participants will be randomly allocated to receive either transdermal testosterone or identical placebo for 26 weeks. The primary outcome will be body weight-corrected power (watts/kg) determined from the maximal vertical jump test on a Leonardo Mechanography Ground Reaction Force Platform (Novotec Medical GmbH). This innovative technology allows for measurement of force, velocity and centre of gravity/sway. It is reproducible and appropriate for older women. Secondary outcomes include grip strength, balance, proprioception, coordination, performance, endurance, and fatiguing (all measured using Leonardo Mechanography), body composition, bone mineral density (BMD), and health-related quality of life. This study addresses the conditions highlighted in the National Women’s Health Strategy 2020-2030 as being of the greatest significance and urgency for older women, who are notably underrepresented in research. It will generate new knowledge in testosterone action and therapy in relation to the preservation of muscle mass and function in postmenopausal women, and potentially provide evidence for novel approaches to prolong the morbidity-free life span of Australian women. This study will provide much needed reference data, presently lacking, for the effect of transdermal testosterone on preservation of muscle mass and function, which will inform the design of future studies of testosterone and other potential therapies. The findings will lead to high impact publications, and potentially transformative interventions ensured by Prof Davis’s standing as the world expert on testosterone in women.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
124550
0
Prof Susan Davis
Query!
Address
124550
0
The Women’s Health Research Program,
School of Public Health and Preventive Medicine
Monash University
553 St Kilda Rd,
Melbourne, Victoria 3004
Query!
Country
124550
0
Australia
Query!
Phone
124550
0
+61 3 9903 0827
Query!
Fax
124550
0
+61 3 9903 0828
Query!
Email
124550
0
[email protected]
Query!
Contact person for public queries
Name
124551
0
Susan Davis
Query!
Address
124551
0
The Women’s Health Research Program,
School of Public Health and Preventive Medicine
Monash University
553 St Kilda Rd,
Melbourne, Victoria 3004
Query!
Country
124551
0
Australia
Query!
Phone
124551
0
+61 3 9903 0827
Query!
Fax
124551
0
+61 3 9903 0828
Query!
Email
124551
0
[email protected]
Query!
Contact person for scientific queries
Name
124552
0
Susan Davis
Query!
Address
124552
0
The Women’s Health Research Program,
School of Public Health and Preventive Medicine
Monash University
553 St Kilda Rd,
Melbourne, Victoria 3004
Query!
Country
124552
0
Australia
Query!
Phone
124552
0
+61 3 9903 0827
Query!
Fax
124552
0
+61 3 9903 0828
Query!
Email
124552
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Doc. No.
Type
Citation
Link
Email
Other Details
Attachment
18304
Study protocol
[email protected]
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF